Approval · Notice of Compliance 23764 · 2020
PRIMAXIN: Notice of Compliance 23764
Issued June 10, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23764
- Date
- June 10, 2020
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To propose changes in the clinical dosing recommendations
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIMAXIN | Not yet assigned | — |
Medicinal ingredients
- IMIPENEM 500 MG per VIAL
- CILASTATIN SODIUM 500 MG per VIAL